Overview

A Phase I/II Study of Diffuse Large B-cell Lymphoma

Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
For continuous variables, mean, median, minimum, and maximum will be used for the descriptive purpose. For categorical variables, frequency and percentage will be used for descriptive statistics. The variables of OS will be estimated by the Kaplan-Meier method. Differences between groups will be calculated using the log-rank test for univariate analysis. Cox's proportional hazards model will be employed to test independent prognostic factors. All calculations will be performed using the Statistical Package of Social Sciences software, version 17.0 (SPSS, Inc., Chicago, IL, USA). The level of statistical significance will be set at 0.05 for all tests.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital
China Medical University Hospital
Shin Kong Wu Huo-Shih Memorial Hospital
Taipei Veterans General Hospital, Taiwan
Treatments:
Paclitaxel
Rituximab